Leo Puri has been named the new chairman of Fortis Healthcare Ltd.’s board of directors, with effect from December 27, 2024. With the goal of guiding Fortis towards innovation, expansion, and sustained leadership in the healthcare industry, Puri, an independent and non-executive director, will assume this leadership position and set the company’s strategic course.
On the proposal of the nomination and compensation committee, the Fortis board authorized the appointment. The appointment of Leo Puri, an independent director with a five-year tenure, is contingent upon shareholder approval. This action is a component of Fortis’ larger initiatives to fortify its leadership team and improve its standing in the healthcare sector.
Puri has been a pioneer in the corporate and financial industries for more than 40 years. He has held high-profile roles in well-known Indian and international organizations. He now serves on the boards of Dr. Reddy’s Laboratories, Hindustan Unilever, and Tata Sons. Puri’s broad expertise in a variety of businesses provides strategic insights that can help Fortis in its quest for superior healthcare services.
Puri has held the positions of Managing Director at UTI Asset Management Company, Senior Partner at McKinsey & Company, Executive Chairman for South & Southeast Asia at JP Morgan Chase, and Managing Director and General Partner at Warburg Pincus. His extensive knowledge of financial management, governance, and business strategy will be crucial in shaping Fortis’ long-term goals.
With a network of 28 healthcare facilities that includes hospitals, diagnostic centers, and specialized day care services, Fortis Healthcare is one of India’s top healthcare providers. Currently, the company’s network has about 4,700 operational beds. Due to the rising need for high-quality healthcare services in India, Fortis is concentrating on enhancing its healthcare delivery skills at the moment of Puri’s appointment.
Indrajit Banerjee’s temporary term as Chairman, which began on October 1, 2024, comes to an end with Puri’s appointment. In addition to remaining on the board, Banerjee will continue to serve on other company committees.
Fortis Healthcare has revealed that its consolidated net profit for the second quarter of FY25 increased by 4.99% to Rs 193.08 crore. This expansion was ascribed to a 12.34% rise in operating revenue, underscoring the business’s strong performance as it keeps growing its offerings nationwide.
SOURCE :
BUSINESS STANDARD
